What's new? Log in Free sign up

Filing search / Cidara Therapeutics, Inc. / "Tenure"

Search information

Cidara Therapeutics, Inc.

Companies

"Tenure"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

6 results

Newest first Best match first

CDTX Cidara Therapeutics, Inc.

Definitive proxy

mission to help protect the world against infectious diseases. He first joined Dynavax in 2004 and, during his twenty-year tenure with Dynavax … billion COVID-19 vaccine doses to vaccine developers around the world. Under Mr. Spencer’s tenure as CEO, the company has established HEPLISAV-B®

3 Jun 24

4:36pm

CDTX Cidara Therapeutics, Inc.

Preliminary proxy

protect the world against infectious diseases. He first joined Dynavax in 2004 and, during his twenty-year tenure with Dynavax, served in various … -19 vaccine doses to vaccine developers around the world. Under Mr. Spencer’s tenure as CEO, the company has established HEPLISAV-B® as the leader

23 May 24

4:59pm

CDTX Cidara Therapeutics, Inc.

Definitive proxy

. Dr. Rocklage has notified us that he will not stand for reelection at the Annual Meeting. As such, Dr. Rocklage’s tenure on the Board will come … . As such, Dr. Rocklage's tenure on the Board will come to an end as of the conclusion of the Annual Meeting. Accordingly, the Board, upon the recommendation

26 Apr 19

4:15pm

CDTX Cidara Therapeutics, Inc.

Definitive proxy

will not stand for reelection at the Annual Meeting. As such, Mr. Perez’ tenure on the Board will come to an end as of the conclusion of the Annual Meeting

27 Apr 18

8:07am

CDTX Cidara Therapeutics, Inc.

Draft registration statement

by Cubist Pharmaceuticals in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from … . During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration, or FDA

Draft registration statement

Prev
1
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.